Moreover, analysis of the inactivation rate in large-scale studies using clinical specimens revealed that SETD2 may occupy a third important place in ccRCC development, inferior only to VHL and PBRM1 [22]. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.